Hormonal
Obesity is a significant risk factor for kidney cancer, with a 5 kg/m2 higher BMI associated with a 25% higher risk of kidney cancers, and 10-26% of all kidney cancers attributable to excess weight.
Maintaining a healthy weight significantly reduces your risk of developing kidney cancer. Higher body weight is linked to a 25% increase in kidney cancer risk for every 5 units of BMI increase. This risk is driven by hormonal changes and inflammation caused by excess fat tissue. Weight management is a proven strategy for cancer prevention.
In a population-based study of 5.24 million individuals from the UK, a 5 kg/m2 higher BMI was associated with a 25% higher risk of kidney cancers, with 10% of all kidney cancers attributable to excess weight... Another large analysis examining the global burden of obesity on malignancies estimated that 17% and 26% of all kidney cancers in men and women, respectively, were attributable to excess weight.
Why this rating
Based on large population-based studies (5.24 million individuals) and meta-analyses of 221 studies.
Source
Obesity and kidney disease: hidden consequences of the epidemic
Csaba P. Kövesdy et al. · Revista médica de Chile · 2017
DOI 10.4067/s0034-98872017000300001
More from this paper
- High body mass index (BMI) and obesity are strong, independent risk factors for the development and progression of chronic kidney disease (CKD), end-stage renal disease (ESRD), and obesity-related glomerulopathy (ORG).Good
- Obesity increases the risk of nephrolithiasis (kidney stones) through mechanisms including lower urine pH, increased urinary oxalate, uric acid, and sodium excretion, and insulin resistance-induced acidic urine.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →